<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336760">
  <stage>Registered</stage>
  <submitdate>4/04/2011</submitdate>
  <approvaldate>6/04/2011</approvaldate>
  <actrnumber>ACTRN12611000357954</actrnumber>
  <trial_identification>
    <studytitle>Tyrosine supplementation in preventing the cognitive effects of psychosocial stress</studytitle>
    <scientifictitle>Tyrosine supplementation versus placebo in preventing the cognitive effects of psychosocial stress in healthy adults</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Stress</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Studies of normal psychology, cognitive function and behaviour</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Once off administration of an oral solution containing either the natural amino acid tyrosine (at a dose of either 100mg/kg or 200mg/kg) or a placebo to healthy adult (male and female) volunteers, two hours prior to exposure to psychosocial stressor (Trier Social Stress Test). To be administered randomly and in a blinded manner</interventions>
    <comparator>Placebo (i.e. oral glucose solution)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in neurocognition as measured by neurocogntive tests battery including simple and choice reaction time, verbal episodic memory, groton maze learning task</outcome>
      <timepoint>To be measured during one day of testing - at baseline, immediately following administration of Trier Social Stress Test and again one hour later</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in biochemical markers of stress (salivary cortisol and alpha-amylase) and central dopamine activity (serum prolactin)</outcome>
      <timepoint>To be measured during one day of testing - at baseline, immediately pre- and post-administration of Trier Social Stress Test and again one hour later</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy adult volunteers</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Past or present mental illness
Family history of mental illness
Any medication or illicit substance use
Pregnant</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealed through the use of an "off-site" allocation schedule. The holder of the schedule contacted following enrollment of a subject</concealment>
    <sequence>Simple randomisation by using a randomisation table created by a computer</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/05/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Lanny Bochsler</primarysponsorname>
    <primarysponsoraddress>Department of Psychiatry 
University of Melbourne
Austin Health
145 Studley Rd
Heidelberg Victoria 3084</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Associate Professor James Olver</othercollaboratorname>
      <othercollaboratoraddress>Department of Psychiatry 
University of Melbourne
Austin Health
145 Studley Rd
Heidelberg Victoria 3084</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Associate Professor Trevor Norman</othercollaboratorname>
      <othercollaboratoraddress>Department of Psychiatry 
University of Melbourne
Austin Health
145 Studley Rd
Heidelberg Victoria 3084</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to evaluate the effects of the administration of the natural amino acid, tyrosine, compared with that of a placebo on the cognitive functioning of healthy adult volunteers subjected to an acute psychosocial stress event. 

This is based on the hypothesis that pre-test administration with tyrosine will prevent or reduce the negative impact of psychosocial stress on a broad range of cognitive tasks through its effect on neurotransmitter functioning</summary>
    <trialwebsite>Nil</trialwebsite>
    <publication>Nil</publication>
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Austin Health
145 Studley Rd
Heidelberg Victoria 3084</ethicaddress>
      <ethicapprovaldate />
      <hrec>EC00204</hrec>
      <ethicsubmitdate>16/03/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Lanny Bochsler</name>
      <address>Department of Psychiatry
University of Melbourne
Austin Health
145 Studley Rd
Heidelberg Victoria 3084</address>
      <phone>+61 3 94965000</phone>
      <fax />
      <email>lanny.bochsler@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ann Pisarevsky</name>
      <address>Department of Psychiatry
University of Melbourne
Austin Health
145 Studley Rd
Heidelberg Victoria 3084</address>
      <phone>+61 3 94965000</phone>
      <fax />
      <email>annp@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>